NASDAQ:NBIX - Neurocrine Biosciences Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$77.31 -2.05 (-2.58 %)
(As of 02/22/2019 01:27 AM ET)
Previous Close$79.36
Today's Range$77.15 - $79.7375
52-Week Range$64.72 - $126.98
Volume845,188 shs
Average Volume1.06 million shs
Market Capitalization$7.02 billion
P/E Ratio351.41
Dividend YieldN/A
Beta1.89

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $102.2817, suggesting that the stock has a possible upside of 32.30%. The high price target for NBIX is $135.00 and the low price target for NBIX is $17.07. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.892.943.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $102.2817$101.4483$124.8824$119.25
Price Target Upside: 32.30% upside11.14% upside41.13% upside2.26% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/6/2019Bank of AmericaLower Price TargetBuy$124.00 ➝ $117.00MediumView Rating Details
2/6/2019Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
1/30/2019HC WainwrightReiterated RatingBuyMediumView Rating Details
1/29/2019OppenheimerSet Price TargetBuy$105.00MediumView Rating Details
1/24/2019Needham & Company LLCDowngradeBuy ➝ HoldLowView Rating Details
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$97.00 ➝ $100.00MediumView Rating Details
12/13/2018Robert W. BairdLower Price TargetOutperform$131.00 ➝ $96.00MediumView Rating Details
12/13/2018Leerink SwannLower Price TargetMarket Perform$110.00 ➝ $84.00MediumView Rating Details
12/13/2018Canaccord GenuityLower Price TargetBuy$111.00 ➝ $100.00MediumView Rating Details
12/13/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$103.00MediumView Rating Details
12/13/2018BarclaysReiterated RatingBuy$95.00MediumView Rating Details
12/12/2018Stifel NicolausLower Price TargetBuy$115.00 ➝ $17.07HighView Rating Details
11/6/2018Morgan StanleyLower Price TargetOverweight ➝ Buy$145.00 ➝ $135.00LowView Rating Details
11/6/2018Piper Jaffray CompaniesSet Price TargetBuy$111.00HighView Rating Details
9/4/2018ICAPLower Price TargetOutperform$140.00 ➝ $128.00MediumView Rating Details
7/30/2018Jefferies Financial GroupBoost Price TargetBuy$124.00HighView Rating Details
5/7/2018CowenReiterated RatingBuy$100.00LowView Rating Details
5/1/2018Deutsche BankSet Price TargetBuy ➝ Buy$97.00 ➝ $99.00HighView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$83.00 ➝ $109.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
(Data available from 2/22/2017 forward)
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel